BTCC
/
BTCC Square
/
Global Cryptocurrency
/
GSK Revives Shelved Drug Amid Political Tailwinds in Bid to Regain Pharma Standing
GSK Revives Shelved Drug Amid Political Tailwinds in Bid to Regain Pharma Standing
6
3
BTCCSquare news:
GlaxoSmithKline (GSK) is leveraging U.S. political dynamics to reinvigorate its pharmaceutical pipeline, including the controversial reapproval of discontinued drug Leucovorin. The London-based firm, which once marketed the therapy as Wellcovorin, secured FDA clearance under pressure from the TRUMP administration to address autism—a move lacking robust clinical evidence but rich in political symbolism.
The timing of the decision, coinciding with a Trump-Kennedy autism event, underscores how policy shifts can reshape drug development priorities. GSK’s stock has outperformed rivals Pfizer and Merck over the past year, suggesting investor Optimism about its strategic pivot.
By:
